Ana S Guerreiro Stucklin1,2, Vijay Ramaswamy1,2, Craig Daniels2, Michael D Taylor2,3. 1. The Division of Haematology/Oncology, The Hospital for Sick Children. 2. The Arthur and Sonia Labatt Brain Tumour Research Centre and the Developmental & Stem Cell Biology Program, The Hospital for Sick Children. 3. Department of Surgery and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Abstract
PURPOSE OF REVIEW: Brain tumors are the most common solid tumors and leading cause of cancer-related death in children. The advent of large-scale genomics has resulted in a plethora of profiling studies that have mapped the genetic and epigenetic landscapes of pediatric brain tumors, ringing in a new era of precision diagnostics and targeted therapies. In this review, we highlight the most recent findings, focusing on studies published after 2015, and discuss how new evidence is changing the care of children with brain tumors. RECENT FINDINGS: Genome-wide and epigenome-wide profiling data have revealed distinct tumor entities within, virtually, all pediatric brain tumor groups including medulloblastoma; ependymoma; high-grade and low-grade gliomas; atypical teratoid/rhabdoid tumors; and other embryonal tumors, previously called CNS primitive neuroectodermal tumors. Whenever integrated with clinical information, many molecular alterations emerge as powerful prognostic markers and should thus be used to stratify patients and tailor therapies. SUMMARY: Optimal integration of this newly emerging knowledge in a timely and meaningful way into clinical care is a remarkable task and a matter of active debate. The historical morphology-based classification of tumors is being replaced by a genetic-based classification, and the first generation of molecularly informed clinical trials is underway.
PURPOSE OF REVIEW: Brain tumors are the most common solid tumors and leading cause of cancer-related death in children. The advent of large-scale genomics has resulted in a plethora of profiling studies that have mapped the genetic and epigenetic landscapes of pediatric brain tumors, ringing in a new era of precision diagnostics and targeted therapies. In this review, we highlight the most recent findings, focusing on studies published after 2015, and discuss how new evidence is changing the care of children with brain tumors. RECENT FINDINGS: Genome-wide and epigenome-wide profiling data have revealed distinct tumor entities within, virtually, all pediatric brain tumor groups including medulloblastoma; ependymoma; high-grade and low-grade gliomas; atypical teratoid/rhabdoid tumors; and other embryonal tumors, previously called CNS primitive neuroectodermal tumors. Whenever integrated with clinical information, many molecular alterations emerge as powerful prognostic markers and should thus be used to stratify patients and tailor therapies. SUMMARY: Optimal integration of this newly emerging knowledge in a timely and meaningful way into clinical care is a remarkable task and a matter of active debate. The historical morphology-based classification of tumors is being replaced by a genetic-based classification, and the first generation of molecularly informed clinical trials is underway.
Authors: Jared T Ahrendsen; Mariella G Filbin; Susan N Chi; Peter E Manley; Karen D Wright; Pratiti Bandopadhayay; Jessica R Clymer; Kee Kiat Yeo; Mark W Kieran; Robert Jones; Hart G Lidov; Keith L Ligon; Sanda Alexandrescu Journal: J Neurooncol Date: 2019-09-30 Impact factor: 4.130
Authors: M Benesch; T Perwein; G Apfaltrer; T Langer; A Neumann; I B Brecht; M U Schuhmann; H Cario; M C Frühwald; K Vollert; M van Buiren; M Y Deng; A Seitz; C Haberler; M Mynarek; C Kramm; F Sahm; P A Robe; J W Dankbaar; K V Hoff; M Warmuth-Metz; B Bison Journal: AJNR Am J Neuroradiol Date: 2022-09-22 Impact factor: 4.966
Authors: Patryk Skowron; Hamza Farooq; Florence M G Cavalli; A Sorana Morrissy; Michelle Ly; Liam D Hendrikse; Evan Y Wang; Haig Djambazian; Helen Zhu; Karen L Mungall; Quang M Trinh; Tina Zheng; Shizhong Dai; Ana S Guerreiro Stucklin; Maria C Vladoiu; Vernon Fong; Borja L Holgado; Carolina Nor; Xiaochong Wu; Diala Abd-Rabbo; Pierre Bérubé; Yu Chang Wang; Betty Luu; Raul A Suarez; Avesta Rastan; Aaron H Gillmor; John J Y Lee; Xiao Yun Zhang; Craig Daniels; Peter Dirks; David Malkin; Eric Bouffet; Uri Tabori; James Loukides; François P Doz; Franck Bourdeaut; Olivier O Delattre; Julien Masliah-Planchon; Olivier Ayrault; Seung-Ki Kim; David Meyronet; Wieslawa A Grajkowska; Carlos G Carlotti; Carmen de Torres; Jaume Mora; Charles G Eberhart; Erwin G Van Meir; Toshihiro Kumabe; Pim J French; Johan M Kros; Nada Jabado; Boleslaw Lach; Ian F Pollack; Ronald L Hamilton; Amulya A Nageswara Rao; Caterina Giannini; James M Olson; László Bognár; Almos Klekner; Karel Zitterbart; Joanna J Phillips; Reid C Thompson; Michael K Cooper; Joshua B Rubin; Linda M Liau; Miklós Garami; Peter Hauser; Kay Ka Wai Li; Ho-Keung Ng; Wai Sang Poon; G Yancey Gillespie; Jennifer A Chan; Shin Jung; Roger E McLendon; Eric M Thompson; David Zagzag; Rajeev Vibhakar; Young Shin Ra; Maria Luisa Garre; Ulrich Schüller; Tomoko Shofuda; Claudia C Faria; Enrique López-Aguilar; Gelareh Zadeh; Chi-Chung Hui; Vijay Ramaswamy; Swneke D Bailey; Steven J Jones; Andrew J Mungall; Richard A Moore; John A Calarco; Lincoln D Stein; Gary D Bader; Jüri Reimand; Jiannis Ragoussis; William A Weiss; Marco A Marra; Hiromichi Suzuki; Michael D Taylor Journal: Nat Commun Date: 2021-03-19 Impact factor: 17.694